Verrica Pharmaceuticals (VRCA) Competitors $6.15 -0.44 (-6.68%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$6.02 -0.14 (-2.20%) As of 08/14/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRCA vs. ALMS, FENC, PRQR, ALLO, TKNO, TVRD, ALEC, CRGX, AVTE, and SOPHShould you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Alumis (ALMS), Adherex Technologies (FENC), ProQR Therapeutics (PRQR), Allogene Therapeutics (ALLO), Alpha Teknova (TKNO), Tvardi Therapeutics (TVRD), Alector (ALEC), CARGO Therapeutics (CRGX), Aerovate Therapeutics (AVTE), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. Verrica Pharmaceuticals vs. Its Competitors Alumis Adherex Technologies ProQR Therapeutics Allogene Therapeutics Alpha Teknova Tvardi Therapeutics Alector CARGO Therapeutics Aerovate Therapeutics SOPHiA GENETICS Verrica Pharmaceuticals (NASDAQ:VRCA) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Which has stronger earnings & valuation, VRCA or ALMS? Verrica Pharmaceuticals has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerrica Pharmaceuticals$7.57M7.68-$76.58M-$8.28-0.74AlumisN/AN/A-$294.23MN/AN/A Is VRCA or ALMS more profitable? Verrica Pharmaceuticals' return on equity of 0.00% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets Verrica PharmaceuticalsN/A N/A -115.48% Alumis N/A -145.20%-111.14% Do analysts rate VRCA or ALMS? Verrica Pharmaceuticals currently has a consensus target price of $80.00, indicating a potential upside of 1,200.81%. Alumis has a consensus target price of $19.80, indicating a potential upside of 351.03%. Given Verrica Pharmaceuticals' higher probable upside, equities research analysts plainly believe Verrica Pharmaceuticals is more favorable than Alumis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Alumis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do insiders & institutionals believe in VRCA or ALMS? 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 40.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, VRCA or ALMS? Verrica Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Alumis has a beta of -1.47, indicating that its share price is 247% less volatile than the S&P 500. Does the media favor VRCA or ALMS? In the previous week, Verrica Pharmaceuticals had 5 more articles in the media than Alumis. MarketBeat recorded 13 mentions for Verrica Pharmaceuticals and 8 mentions for Alumis. Verrica Pharmaceuticals' average media sentiment score of 0.61 beat Alumis' score of 0.47 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVerrica Pharmaceuticals beats Alumis on 9 of the 13 factors compared between the two stocks. Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRCA vs. The Competition Export to ExcelMetricVerrica PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.25M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-0.7422.0530.2725.74Price / Sales7.68742.42459.75115.79Price / CashN/A184.4138.2159.48Price / Book-3.324.838.846.15Net Income-$76.58M$31.61M$3.25B$265.06M7 Day Performance-3.15%4.55%3.72%2.60%1 Month Performance-22.94%5.69%5.86%2.83%1 Year Performance-78.87%12.71%30.25%25.58% Verrica Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRCAVerrica Pharmaceuticals4.5866 of 5 stars$6.15-6.7%$80.00+1,200.8%-80.3%$62.25M$7.57M-0.7440Earnings ReportShort Interest ↓ALMSAlumis2.884 of 5 stars$4.34+0.9%$19.80+356.2%-65.5%$233.94MN/A0.00N/ANews CoverageEarnings ReportAnalyst ForecastGap DownFENCAdherex Technologies2.1377 of 5 stars$8.25-1.0%$13.00+57.6%+60.0%$231.69M$47.54M-16.1810News CoverageGap DownPRQRProQR Therapeutics2.3268 of 5 stars$1.89-12.9%$8.00+323.3%-9.8%$228.31M$20.46M-4.11180Gap DownHigh Trading VolumeALLOAllogene Therapeutics2.9047 of 5 stars$1.03-1.0%$8.44+719.8%-52.4%$227.48M$20K-0.84310Trending NewsEarnings ReportTKNOAlpha Teknova2.4567 of 5 stars$4.41+4.3%$10.00+126.8%+29.4%$226.05M$37.74M-10.50240Gap DownTVRDTvardi TherapeuticsN/A$24.13+0.9%$64.25+166.3%N/A$223.96M$7.14M0.0080News CoveragePositive NewsEarnings ReportALECAlector3.987 of 5 stars$2.23+3.7%$4.17+86.8%-49.4%$217.61M$100.56M-1.92270High Trading VolumeCRGXCARGO Therapeutics2.1194 of 5 stars$4.48-0.2%$15.40+243.8%-73.0%$217.16MN/A-0.97116Positive NewsAVTEAerovate TherapeuticsN/A$7.49+2.3%N/A-87.8%$217.10MN/A-2.5120High Trading VolumeSOPHSOPHiA GENETICS2.974 of 5 stars$3.01-5.3%$8.00+165.8%+0.0%$214.90M$65.17M-6.84520Short Interest ↓ Related Companies and Tools Related Companies ALMS Alternatives FENC Alternatives PRQR Alternatives ALLO Alternatives TKNO Alternatives TVRD Alternatives ALEC Alternatives CRGX Alternatives AVTE Alternatives SOPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRCA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access